-
Mar 01, 2025
-
Mar 01, 2025
-
Mar 01, 2025
-
Mar 01, 2025
-
Mar 01, 2025Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life MeasuresFeb 27, 2025, 16:05 ET Share this article SAN DIEGO, Feb. 27, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq:view more
-
Feb 28, 2025
-
Feb 28, 2025
-
Feb 28, 2025
-
Feb 28, 2025
-
Feb 27, 2025
-
Feb 26, 2025
-
Feb 26, 2025
